Seeking Alpha

Amarantus' ADHD drug performs well in Phase IIa study

  • Amarantus Bioscience's (AMBS) Eltoprazine treatment for adults with ADHD met its primary target in a Phase IIa trial of 47 patients and demonstrated 25% greater efficacy vs a placebo.
  • No serious adverse events took place, while most of the side effects were "mild of moderate." Still, only 36 subjects completed the study.
  • Amarantus is reviewing it options for the further advancement of its ADHD program, including business-development possibilities as the company prepares to up-list to a national stock exchange. (PR)
Comments (11)
  • 25% improvement over placebo shouldnt qualify as proof of effectiveness. Especially considering ADHD testing is a a qualitative assessment.
    4 Feb, 09:36 AM Reply Like
  • It is statistically significant, which is all that matters. Like you said, it is a qualitative assessment, which means that lots of placebo patients will "think" they are getting better because they want to be getting better. It makes sense that both numbers might be artificially inflated by some degree. What is important is that:

     

    1. There is improvement.
    2. It is statistically significant.
    4 Feb, 09:39 AM Reply Like
  • That is a very low threshold, considering doctors can force patients to take such drugs.
    4 Feb, 09:41 AM Reply Like
  • The better way to look at this would be to dig up the Adderall Phase 2a studies and see how it compared to the placebo. I have not done this.
    4 Feb, 10:35 AM Reply Like
  • The fact that it's measurable and there is an improvement means that they are on the right track. A lot of science is trial and error and rarely does it happen like in a movie, where they go from idea to completed product in one episode. The fact that there is measurable improvement gives them a positive development to work with and lets them know they are on the right track. Now they can work on refining and improving what they found and making it better, and then hopefully show greater efficacy in the next round of testing...
    4 Feb, 10:19 AM Reply Like
  • Keep in mind this is still only Phase IIa...
    4 Feb, 10:19 AM Reply Like
  • This study and resulting information is over four years old, why is it being revisited now?
    4 Feb, 12:10 PM Reply Like
  • If that is the case then it looks like the PR machine is out in full force. I hope that is not the case. They need good PR not inflated old news
    4 Feb, 03:33 PM Reply Like
  • Do you have a link to information time stamped as old? I have received this information today not just through seeking Alpha but through my brokerage as well.
    4 Feb, 03:46 PM Reply Like
  • The drug is an older drug that they recently came into ownership of (in January 2014). They are clearly using the PRs to let people know why they like this drug and how they will be utilizing it going forward. Some of the reports are of course old since they have not yet run any new studies since they just received the drug.
    4 Feb, 04:00 PM Reply Like
  • Ah ok thanks Chris that explains why the news didn't really move the needle on the stock price.
    4 Feb, 04:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)